150 related articles for article (PubMed ID: 35791496)
1. Impact of vaccination on COVID-19 outcome in multiple sclerosis.
Bsteh G; Gradl C; Heschl B; Hegen H; Di Pauli F; Assar H; Leutmezer F; Traxler G; Krajnc N; Zulehner G; Hiller MS; Rommer P; Wipfler P; Guger M; Enzinger C; Berger T;
Eur J Neurol; 2022 Jul; ():. PubMed ID: 35791496
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 severity and mortality in multiple sclerosis are not associated with immunotherapy: Insights from a nation-wide Austrian registry.
Bsteh G; Assar H; Hegen H; Heschl B; Leutmezer F; Di Pauli F; Gradl C; Traxler G; Zulehner G; Rommer P; Wipfler P; Guger M; Enzinger C; Berger T;
PLoS One; 2021; 16(7):e0255316. PubMed ID: 34314457
[TBL] [Abstract][Full Text] [Related]
3. Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study.
Bsteh G; Dürauer S; Assar H; Hegen H; Heschl B; Leutmezer F; Pauli FD; Gradl C; Traxler G; Zulehner G; Rommer P; Wipfler P; Guger M; Höftberger R; Enzinger C; Berger T
Mult Scler; 2021 Dec; 27(14):2209-2218. PubMed ID: 34595968
[TBL] [Abstract][Full Text] [Related]
4. Risk of breakthrough COVID-19 after vaccination among people with multiple sclerosis on disease-modifying therapies.
Spierer R; Lavi I; Bloch S; Mazar M; Golan D
J Neurol; 2023 Oct; 270(10):4632-4639. PubMed ID: 37589743
[TBL] [Abstract][Full Text] [Related]
5. Antibodies against SARS-CoV-2 S and N proteins in relapsing-remitting multiple sclerosis patients treated with disease-modifying therapies.
Kulikowska J; Czarnowska A; Gudowska-Sawczuk M; Kulczyńska-Przybik A; Bazylewicz M; Collins F; Chorąży M; Mroczko B; Kochanowicz J; Kapica-Topczewska K; Kułakowska A
Neurol Neurochir Pol; 2023; 57(1):121-130. PubMed ID: 36421067
[TBL] [Abstract][Full Text] [Related]
6. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
Iaffaldano P; Lucisano G; Manni A; Paolicelli D; Patti F; Capobianco M; Brescia Morra V; Sola P; Pesci I; Lus G; De Luca G; Lugaresi A; Cavalla P; Montepietra S; Maniscalco GT; Granella F; Ragonese P; Vianello M; Brambilla L; Totaro R; Toscano S; Malucchi S; Petracca M; Moiola L; Ferraro D; Lepore V; Mosconi P; Ponzio M; Tedeschi G; Comi G; Battaglia MA; Filippi M; Amato MP; Trojano M;
Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35046084
[TBL] [Abstract][Full Text] [Related]
7. B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications.
Iannetta M; Landi D; Cola G; Campogiani L; Malagnino V; Teti E; Coppola L; Di Lorenzo A; Fraboni D; Buccisano F; Grelli S; Mozzani M; Zingaropoli MA; Ciardi MR; Nisini R; Bernardini S; Andreoni M; Marfia GA; Sarmati L
Front Immunol; 2021; 12():796482. PubMed ID: 35111162
[TBL] [Abstract][Full Text] [Related]
8. The impact of hybrid immunity on immune responses after SARS-CoV-2 vaccination in persons with multiple sclerosis treated with disease-modifying therapies.
Rabenstein M; Thomas OG; Carlin G; Khademi M; Högelin KA; Malmeström C; Axelsson M; Brandt AF; Gafvelin G; Grönlund H; Kockum I; Piehl F; Lycke J; Olsson T; Hessa T
Eur J Neurol; 2023 Dec; 30(12):3789-3798. PubMed ID: 37522464
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 serology among people with multiple sclerosis on disease-modifying therapies after BBIBP-CorV (Sinopharm) inactivated virus vaccination: Same story, different vaccine.
Etemadifar M; Sedaghat N; Nouri H; Lotfi N; Chitsaz A; Khorvash R; Zolfaghari H; Ghasemi Movaghar A; Pourabbas M; Salari M
Mult Scler Relat Disord; 2022 Jan; 57():103417. PubMed ID: 34875487
[TBL] [Abstract][Full Text] [Related]
10. Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: A meta-analysis.
Wu X; Wang L; Shen L; Tang K
EBioMedicine; 2022 Jul; 81():104102. PubMed ID: 35759920
[TBL] [Abstract][Full Text] [Related]
11. Vaccine hesitancy among people with multiple sclerosis.
Yap SM; Al Hinai M; Gaughan M; Callanan I; Kearney H; Tubridy N; McGuigan C
Mult Scler Relat Disord; 2021 Nov; 56():103236. PubMed ID: 34507240
[TBL] [Abstract][Full Text] [Related]
12. Humoral immune response to SARS-CoV-2 third vaccination in patients with multiple sclerosis and healthy controls: A prospective multicenter study.
Krajnc N; Hegen H; Traxler G; Leutmezer F; Di Pauli F; Kornek B; Rommer P; Zulehner G; Riedl K; Dürauer S; Bauer A; Kratzwald S; Klotz S; Winklehner M; Deisenhammer F; Guger M; Höftberger R; Berger T; Bsteh G
Mult Scler Relat Disord; 2022 Sep; 65():104009. PubMed ID: 35797803
[TBL] [Abstract][Full Text] [Related]
13. mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity-Does it matter?
Tütüncü M; Demir S; Arslan G; Dinç Ö; Şen S; Gündüz T; Uzunköprü C; Gümüş H; Tütüncü M; Akçin R; Özakbaş S; Köseoğlu M; Bünül SD; Gezen O; Tezer DÇ; Baba C; Özen PA; Koç R; Elverdi T; Uygunoğlu U; Kürtüncü M; Beckmann Y; Doğan İG; Turan ÖF; Boz C; Terzi M; Tuncer A; Saip S; Karabudak R; Kocazeybek B; Efendi H; Bilge U; Siva A
Mult Scler Relat Disord; 2023 Jul; 75():104761. PubMed ID: 37247488
[TBL] [Abstract][Full Text] [Related]
14. Effect of multiple sclerosis disease-modifying therapies on the real-world effectiveness of two doses of BBIBP-CorV (Sinopharm) vaccine.
Etemadifar M; Abhari AP; Nouri H; Eighani N; Salari M; Sedaghat N
J Neurol Sci; 2023 Jan; 444():120518. PubMed ID: 36521195
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 vaccination uptake in people with multiple sclerosis compared to the general population.
Mayer D; Barun B; Lazibat K; Lasić S; Adamec I; Gabelić T; Krbot Skorić M; Habek M
Acta Neurol Belg; 2023 Dec; 123(6):2269-2275. PubMed ID: 37261658
[TBL] [Abstract][Full Text] [Related]
16. Predictors for insufficient SARS-CoV-2 vaccination response upon treatment in multiple sclerosis.
Schraad M; Uphaus T; Runkel S; Hitzler W; Bittner S; Zipp F
EBioMedicine; 2023 Jan; 87():104411. PubMed ID: 36535106
[TBL] [Abstract][Full Text] [Related]
17. Insights from Real-World Practice: The Dynamics of SARS-CoV-2 Infections and Vaccinations in a Large German Multiple Sclerosis Cohort.
Inojosa H; Schriefer D; Atta Y; Dillenseger A; Proschmann U; Schleußner K; Woopen C; Ziemssen T; Akgün K
Vaccines (Basel); 2024 Mar; 12(3):. PubMed ID: 38543899
[TBL] [Abstract][Full Text] [Related]
18. Preserved T cell responses to SARS-CoV-2 in anti-CD20 treated multiple sclerosis.
Schwarz T; Otto C; Jones TC; Pache F; Schindler P; Niederschweiberer M; Schmidt FA; Drosten C; Corman VM; Ruprecht K
Mult Scler; 2022 Jun; 28(7):1041-1050. PubMed ID: 35575234
[TBL] [Abstract][Full Text] [Related]
19. COVID-19 Vaccination in Multiple Sclerosis and Inflammatory Diseases: Effects from Disease-Modifying Therapy, Long-Term Seroprevalence and Breakthrough Infections.
Jakimovski D; Zakalik K; Awan S; Kavak KS; Pennington P; Hojnacki D; Kolb C; Lizarraga AA; Eckert SP; Sarrosa R; Vineetha K; Edwards K; Weinstock-Guttman B
Vaccines (Basel); 2022 Apr; 10(5):. PubMed ID: 35632451
[TBL] [Abstract][Full Text] [Related]
20. A National Representative, Cross-Sectional Study by the Hellenic Academy of NeuroImmunology (HEL.A.NI.) on COVID-19 and Multiple Sclerosis: Overall Impact and Willingness Toward Vaccination.
Boziki M; Styliadis C; Bakirtzis C; Grigoriadou E; Sintila AS; Nikolaidis I; Vrienniou A; Geys L; Pelidou SH; Probert L; Papazisis G; Bamidis P; Grigoriadis N
Front Neurol; 2021; 12():757038. PubMed ID: 34899577
[No Abstract] [Full Text] [Related]
[Next] [New Search]
